SITAJAN D Tablet is a scientifically developed oral antidiabetic formulation that combines the DPP-4 inhibitor Sitagliptin with the well-established biguanide Metformin Hydrochloride (Extended Release). This dual-action therapy is designed for adult patients with type 2 diabetes mellitus who require better glycemic control than achieved by monotherapy alone. The combination of Sitagliptin and Metformin targets different physiological pathways to provide a synergistic effect in lowering both fasting plasma glucose (FPG) and postprandial glucose (PPG) levels.

Sitagliptin enhances the levels of active incretin hormones by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4). This action increases insulin secretion and decreases glucagon levels in a glucose-dependent manner, resulting in improved glycemic control with minimal risk of hypoglycemia. Metformin, on the other hand, works by decreasing hepatic glucose production and improving insulin sensitivity at the cellular level. The extended-release formulation of Metformin provides sustained glucose-lowering effects and enhances patient compliance by reducing gastrointestinal side effects.

SITAJAN D is especially beneficial for newly diagnosed patients, those with a history of insulin resistance, or individuals who have not achieved adequate control on Metformin alone. It is usually prescribed as a once-daily tablet, preferably with the evening meal, allowing for better control of nighttime and early morning glucose levels. Clinical studies have shown that the combination improves HbA1c levels significantly while maintaining a favorable weight and cardiovascular risk profile.

The tablet is produced by Bluepill Express in WHO-GMP, ISO, and USFDA-standard facilities using advanced granulation and coating technologies to ensure uniform drug distribution and extended drug release. Strict in-process controls and validated analytical methods are employed to verify each batch for identity, potency, purity, dissolution, stability, and absence of microbial or heavy metal contamination.

SITAJAN D is offered in a range of strengths to accommodate patient-specific treatment plans. Available combinations typically include Sitagliptin 50 mg or 100 mg with Metformin ER 500 mg, 850 mg, or 1000 mg. Each tablet is packaged in alu-alu or blister strips to preserve product integrity and shelf life. Bluepill Express offers custom labeling, international regulatory support, and logistics coordination to ensure timely delivery and market compliance.

Our regulatory dossier includes Certificate of Analysis (COA), Certificate of Pharmaceutical Product (COPP), Stability Data, MSDS, and Site Master File. The SITAJAN D brand is exported to major markets in Asia, the Middle East, Africa, and Latin America. It is a trusted solution in national diabetes care programs and by hospital procurement authorities seeking cost-effective and reliable anti-diabetic medications.

Bluepill Express prioritizes therapeutic efficacy, affordability, and global standards in all its manufacturing operations. The development of SITAJAN D aligns with our mission to offer accessible treatments for chronic diseases like diabetes, which is increasing in prevalence worldwide. Through strategic partnerships with international distributors and government tenders, we ensure uninterrupted availability of SITAJAN D in high-demand markets.